P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples

Merce Jorda, Carmen Gomez-Fernandez, Monica Garcia-Buitrago, Fatemeh Mousavi, Gail Walker, Aldo Mejias, Gustavo Fernandez, Parvin Ganjei-Azar

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

BACKGROUND: Bevacizumab in combination with carboplatin and paclitaxel improves overall response and survival in patients with advanced or recurrent nonsmall cell lung carcinoma. However, this drug is not recommended in patients with squamous cell carcinoma or neoplasms with a dominant squamous component. Therefore, identification of squamous cell differentiation has therapeutic implications. In many instances, cytology is the diagnostic tool of choice; however, routine cytomorphology is limited in classification of nonsmall cell carcinomas into squamous and nonsquamous subtypes. The aim of this study was to identify the value of p63 immunocytochemical analysis in this distinction. METHODS: Review of cytology records identified 51 consecutive pulmonary specimens (16 fine needle aspiration samples, 15 washes, 12 brushes, and 8 lavages) with the diagnosis of nonsmall cell lung carcinoma (9 carcinomas with squamous differentiation and 42 carcinomas without squamous differentiation). Histologically, they all proved to be nonsmall cell carcinomas, 26 with squamous differentiation and 25 without squamous differentiation. p63 immunocytochemical stain was performed on archival alcohol-fixed Papanicolaou-stained cytology slides using standard immunocytochemical methods. RESULTS: Twenty-three (88%) of the 26 histologically proven squamous cell carcinomas were positive for p63 on cytologic smears. By using p63 immunocytochemistry, the authors detected 14 carcinomas with squamous differentiation not identified by cytomorphology. Smears from all histologically proven carcinomas with squamous differentiation were positive for p63. Sensitivity of cytology for the detection of nonsmall cell carcinoma of lung with squamous differentiation increased from 35% to 88% using p63 immunocytochemistry (P = .001; McNemar test). The squamous component in 4 carcinomas was detected only in cytologic and not in corresponding histologic samples when subsequent p63 immunostaining was performed. CONCLUSIONS: The authors concluded that p63 is a useful marker for the detection of nonsmall cell carcinomas of lung with squamous differentiation when used in cytologic pulmonary samples. p63 immunocytochemistry significantly increases the sensitivity for the identification of lung neoplasms with squamous differentiation from 35% to 88% (P = .001). Therefore, p63 immunocytochemistry may be used in pulmonary cytologic samples of nonsmall cell carcinomas to identify squamous differentiation and to improve therapeutic selection of patients with lung cancer.

Original languageEnglish
Pages (from-to)46-50
Number of pages5
JournalCancer cytopathology
Volume117
Issue number1
DOIs
StatePublished - Dec 1 2009

Fingerprint

Squamous Cell Carcinoma
Carcinoma
Lung
Cell Biology
Immunohistochemistry
Lung Neoplasms
Squamous Cell Neoplasms
Carboplatin
Therapeutic Irrigation
Fine Needle Biopsy
Paclitaxel
Patient Selection
Cell Differentiation
Coloring Agents
Epithelial Cells
Alcohols
Survival
Therapeutics
Pharmaceutical Preparations

Keywords

  • Bevacizumab
  • Nonsmall cell carcinoma
  • P63
  • Squamous differentiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples. / Jorda, Merce; Gomez-Fernandez, Carmen; Garcia-Buitrago, Monica; Mousavi, Fatemeh; Walker, Gail; Mejias, Aldo; Fernandez, Gustavo; Ganjei-Azar, Parvin.

In: Cancer cytopathology, Vol. 117, No. 1, 01.12.2009, p. 46-50.

Research output: Contribution to journalArticle

@article{87a1d18ffb504de08ab66dc0dbe9ff1f,
title = "P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples",
abstract = "BACKGROUND: Bevacizumab in combination with carboplatin and paclitaxel improves overall response and survival in patients with advanced or recurrent nonsmall cell lung carcinoma. However, this drug is not recommended in patients with squamous cell carcinoma or neoplasms with a dominant squamous component. Therefore, identification of squamous cell differentiation has therapeutic implications. In many instances, cytology is the diagnostic tool of choice; however, routine cytomorphology is limited in classification of nonsmall cell carcinomas into squamous and nonsquamous subtypes. The aim of this study was to identify the value of p63 immunocytochemical analysis in this distinction. METHODS: Review of cytology records identified 51 consecutive pulmonary specimens (16 fine needle aspiration samples, 15 washes, 12 brushes, and 8 lavages) with the diagnosis of nonsmall cell lung carcinoma (9 carcinomas with squamous differentiation and 42 carcinomas without squamous differentiation). Histologically, they all proved to be nonsmall cell carcinomas, 26 with squamous differentiation and 25 without squamous differentiation. p63 immunocytochemical stain was performed on archival alcohol-fixed Papanicolaou-stained cytology slides using standard immunocytochemical methods. RESULTS: Twenty-three (88{\%}) of the 26 histologically proven squamous cell carcinomas were positive for p63 on cytologic smears. By using p63 immunocytochemistry, the authors detected 14 carcinomas with squamous differentiation not identified by cytomorphology. Smears from all histologically proven carcinomas with squamous differentiation were positive for p63. Sensitivity of cytology for the detection of nonsmall cell carcinoma of lung with squamous differentiation increased from 35{\%} to 88{\%} using p63 immunocytochemistry (P = .001; McNemar test). The squamous component in 4 carcinomas was detected only in cytologic and not in corresponding histologic samples when subsequent p63 immunostaining was performed. CONCLUSIONS: The authors concluded that p63 is a useful marker for the detection of nonsmall cell carcinomas of lung with squamous differentiation when used in cytologic pulmonary samples. p63 immunocytochemistry significantly increases the sensitivity for the identification of lung neoplasms with squamous differentiation from 35{\%} to 88{\%} (P = .001). Therefore, p63 immunocytochemistry may be used in pulmonary cytologic samples of nonsmall cell carcinomas to identify squamous differentiation and to improve therapeutic selection of patients with lung cancer.",
keywords = "Bevacizumab, Nonsmall cell carcinoma, P63, Squamous differentiation",
author = "Merce Jorda and Carmen Gomez-Fernandez and Monica Garcia-Buitrago and Fatemeh Mousavi and Gail Walker and Aldo Mejias and Gustavo Fernandez and Parvin Ganjei-Azar",
year = "2009",
month = "12",
day = "1",
doi = "10.1002/cncy.20015",
language = "English",
volume = "117",
pages = "46--50",
journal = "Cancer cytopathology",
issn = "1934-662X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples

AU - Jorda, Merce

AU - Gomez-Fernandez, Carmen

AU - Garcia-Buitrago, Monica

AU - Mousavi, Fatemeh

AU - Walker, Gail

AU - Mejias, Aldo

AU - Fernandez, Gustavo

AU - Ganjei-Azar, Parvin

PY - 2009/12/1

Y1 - 2009/12/1

N2 - BACKGROUND: Bevacizumab in combination with carboplatin and paclitaxel improves overall response and survival in patients with advanced or recurrent nonsmall cell lung carcinoma. However, this drug is not recommended in patients with squamous cell carcinoma or neoplasms with a dominant squamous component. Therefore, identification of squamous cell differentiation has therapeutic implications. In many instances, cytology is the diagnostic tool of choice; however, routine cytomorphology is limited in classification of nonsmall cell carcinomas into squamous and nonsquamous subtypes. The aim of this study was to identify the value of p63 immunocytochemical analysis in this distinction. METHODS: Review of cytology records identified 51 consecutive pulmonary specimens (16 fine needle aspiration samples, 15 washes, 12 brushes, and 8 lavages) with the diagnosis of nonsmall cell lung carcinoma (9 carcinomas with squamous differentiation and 42 carcinomas without squamous differentiation). Histologically, they all proved to be nonsmall cell carcinomas, 26 with squamous differentiation and 25 without squamous differentiation. p63 immunocytochemical stain was performed on archival alcohol-fixed Papanicolaou-stained cytology slides using standard immunocytochemical methods. RESULTS: Twenty-three (88%) of the 26 histologically proven squamous cell carcinomas were positive for p63 on cytologic smears. By using p63 immunocytochemistry, the authors detected 14 carcinomas with squamous differentiation not identified by cytomorphology. Smears from all histologically proven carcinomas with squamous differentiation were positive for p63. Sensitivity of cytology for the detection of nonsmall cell carcinoma of lung with squamous differentiation increased from 35% to 88% using p63 immunocytochemistry (P = .001; McNemar test). The squamous component in 4 carcinomas was detected only in cytologic and not in corresponding histologic samples when subsequent p63 immunostaining was performed. CONCLUSIONS: The authors concluded that p63 is a useful marker for the detection of nonsmall cell carcinomas of lung with squamous differentiation when used in cytologic pulmonary samples. p63 immunocytochemistry significantly increases the sensitivity for the identification of lung neoplasms with squamous differentiation from 35% to 88% (P = .001). Therefore, p63 immunocytochemistry may be used in pulmonary cytologic samples of nonsmall cell carcinomas to identify squamous differentiation and to improve therapeutic selection of patients with lung cancer.

AB - BACKGROUND: Bevacizumab in combination with carboplatin and paclitaxel improves overall response and survival in patients with advanced or recurrent nonsmall cell lung carcinoma. However, this drug is not recommended in patients with squamous cell carcinoma or neoplasms with a dominant squamous component. Therefore, identification of squamous cell differentiation has therapeutic implications. In many instances, cytology is the diagnostic tool of choice; however, routine cytomorphology is limited in classification of nonsmall cell carcinomas into squamous and nonsquamous subtypes. The aim of this study was to identify the value of p63 immunocytochemical analysis in this distinction. METHODS: Review of cytology records identified 51 consecutive pulmonary specimens (16 fine needle aspiration samples, 15 washes, 12 brushes, and 8 lavages) with the diagnosis of nonsmall cell lung carcinoma (9 carcinomas with squamous differentiation and 42 carcinomas without squamous differentiation). Histologically, they all proved to be nonsmall cell carcinomas, 26 with squamous differentiation and 25 without squamous differentiation. p63 immunocytochemical stain was performed on archival alcohol-fixed Papanicolaou-stained cytology slides using standard immunocytochemical methods. RESULTS: Twenty-three (88%) of the 26 histologically proven squamous cell carcinomas were positive for p63 on cytologic smears. By using p63 immunocytochemistry, the authors detected 14 carcinomas with squamous differentiation not identified by cytomorphology. Smears from all histologically proven carcinomas with squamous differentiation were positive for p63. Sensitivity of cytology for the detection of nonsmall cell carcinoma of lung with squamous differentiation increased from 35% to 88% using p63 immunocytochemistry (P = .001; McNemar test). The squamous component in 4 carcinomas was detected only in cytologic and not in corresponding histologic samples when subsequent p63 immunostaining was performed. CONCLUSIONS: The authors concluded that p63 is a useful marker for the detection of nonsmall cell carcinomas of lung with squamous differentiation when used in cytologic pulmonary samples. p63 immunocytochemistry significantly increases the sensitivity for the identification of lung neoplasms with squamous differentiation from 35% to 88% (P = .001). Therefore, p63 immunocytochemistry may be used in pulmonary cytologic samples of nonsmall cell carcinomas to identify squamous differentiation and to improve therapeutic selection of patients with lung cancer.

KW - Bevacizumab

KW - Nonsmall cell carcinoma

KW - P63

KW - Squamous differentiation

UR - http://www.scopus.com/inward/record.url?scp=65349083842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349083842&partnerID=8YFLogxK

U2 - 10.1002/cncy.20015

DO - 10.1002/cncy.20015

M3 - Article

C2 - 19347829

AN - SCOPUS:65349083842

VL - 117

SP - 46

EP - 50

JO - Cancer cytopathology

JF - Cancer cytopathology

SN - 1934-662X

IS - 1

ER -